囊性纤维化 2023 年年鉴
Cystic fibrosis year in review 2023.
机构信息
Department of Pediatrics, Children's Hospital of New Orleans, New Orleans, Louisiana, USA.
Department of Pediatrics, Tulane University, New Orleans, Louisiana, USA.
出版信息
Pediatr Pulmonol. 2024 Dec;59(12):3106-3116. doi: 10.1002/ppul.27190. Epub 2024 Jul 26.
Abstract
This past year, there were many important advances for patients with cystic fibrosis (CF). Of the many publications related to CF in 2023, there was further evaluation of highly effective modulator therapy, new assessments and guidelines for clinical manifestations and therapies for CF, advances in newborn screening and diagnosis, and evaluation of outcomes for people with CF transmembrane conductance regulator-related metabolic syndrome/CF screen positive, inconclusive diagnosis. The aim of this review article is not to provide a full assessment of the wide range of articles published in 2023, but to provide a brief review of publication that may lead to changes in clinical care.
摘要
过去一年，囊性纤维化（CF）患者取得了许多重要进展。在 2023 年与 CF 相关的众多出版物中，进一步评估了高效调节剂治疗、CF 临床表现和治疗的新评估和指南、新生儿筛查和诊断的进展，以及 CF 跨膜电导调节因子相关代谢综合征/CF 筛查阳性、结果不确定诊断人群的结局评估。本文的目的不是对 2023 年发表的大量文章进行全面评估，而是简要回顾可能导致临床护理变化的出版物。
相似文献
1
Cystic fibrosis year in review 2023.囊性纤维化 2023 年年鉴
Pediatr Pulmonol. 2024 Dec;59(12):3106-3116. doi: 10.1002/ppul.27190. Epub 2024 Jul 26.
2
Cystic fibrosis year in review 2024.2024年囊性纤维化年度回顾
J Cyst Fibros. 2025 Mar;24(2):218-223. doi: 10.1016/j.jcf.2025.02.012. Epub 2025 Feb 18.
3
Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID).关于囊性纤维化跨膜传导调节因子相关代谢综合征/囊性纤维化筛查阳性、诊断不确定（CRMS/CFSPID）患儿管理的更新指南。
J Cyst Fibros. 2021 Sep;20(5):810-819. doi: 10.1016/j.jcf.2020.11.006. Epub 2020 Nov 27.
4
Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians.囊性纤维化治疗进展及对基层临床医生的启示
Curr Probl Pediatr Adolesc Health Care. 2024 Jun;54(6):101637. doi: 10.1016/j.cppeds.2024.101637. Epub 2024 May 28.
5
Characterization of 223 infants with CFTR-related metabolic syndrome/Cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID) identified during the first three years of newborn screening via IRT-DNA-SEQ in New York State.对纽约州通过IRT-DNA-SEQ新生儿筛查头三年期间确诊的223例患有CFTR相关代谢综合征/囊性纤维化筛查阳性、诊断不确定（CRMS/CFSPID）的婴儿的特征描述。
J Cyst Fibros. 2025 Mar;24(2):404-411. doi: 10.1016/j.jcf.2024.10.015. Epub 2024 Nov 12.
6
Cystic Fibrosis Diagnosis and Newborn Screening.囊性纤维化的诊断与新生儿筛查
Pediatr Clin North Am. 2016 Aug;63(4):599-615. doi: 10.1016/j.pcl.2016.04.004.
7
Advances in Care and Outcomes for Children with Cystic Fibrosis.囊性纤维化患儿的护理和结局进展。
Clin Chest Med. 2024 Sep;45(3):625-637. doi: 10.1016/j.ccm.2024.03.006. Epub 2024 Apr 30.
8
Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.纳入多突变DNA检测的基于人群的新生儿遗传疾病筛查：一个囊性纤维化新生儿筛查模型显示敏感性增加但携带者检测增多。
Pediatrics. 2004 Jun;113(6):1573-81. doi: 10.1542/peds.113.6.1573.
9
Review of Cystic Fibrosis.囊性纤维化综述
Pediatr Ann. 2019 Apr 1;48(4):e154-e161. doi: 10.3928/19382359-20190327-01.
10
Genetic diagnosis in practice: From cystic fibrosis to CFTR-related disorders.临床中的基因诊断：从囊性纤维化到CFTR相关疾病
Arch Pediatr. 2020 Feb;27 Suppl 1:eS25-eS29. doi: 10.1016/S0929-693X(20)30047-6.
引用本文的文献
1
Same-Day Repeatability and 28-Day Reproducibility of Xenon MRI Ventilation in Children With Cystic Fibrosis in a Multi-Site Trial.多中心试验中囊性纤维化患儿氙气MRI通气的同日重复性和28天再现性
J Magn Reson Imaging. 2025 Apr;61(4):1664-1674. doi: 10.1002/jmri.29605. Epub 2024 Sep 11.
本文引用的文献
1
Clinical features associated with pulmonary exacerbation diagnosis in infants and young children with cystic fibrosis.囊性纤维化婴幼儿肺部恶化诊断相关的临床特征。
Pediatr Pulmonol. 2024 Apr;59(4):874-879. doi: 10.1002/ppul.26838. Epub 2023 Dec 22.
2
Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.辅助全身皮质类固醇治疗囊性纤维化肺部加重。
Ann Am Thorac Soc. 2024 May;21(5):716-726. doi: 10.1513/AnnalsATS.202308-673OC.
3
Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.分析伊伐卡托/泰他卡托/艾美卡托起始治疗后囊性纤维化人群的铁状态。
Pediatr Pulmonol. 2024 Mar;59(3):669-678. doi: 10.1002/ppul.26805. Epub 2023 Dec 13.
4
Associations between symptoms of ADHD/ODD and health outcomes in youth with cystic fibrosis.患有囊性纤维化的青少年中注意缺陷多动障碍/对立违抗性障碍症状与健康结局之间的关联。
Pediatr Pulmonol. 2024 Mar;59(3):809-812. doi: 10.1002/ppul.26811. Epub 2023 Dec 13.
5
Risk of CFTR-related disorders and cystic fibrosis in an Italian cohort of CRMS/CFSPID subjects in preschool and school age.意大利一个学前和学龄期 CRMS/CFSPID 受试者队列中与 CFTR 相关疾病和囊性纤维化的风险。
Eur J Pediatr. 2024 Feb;183(2):929-938. doi: 10.1007/s00431-023-05359-5. Epub 2023 Dec 6.
6
Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.囊性纤维化肺部加重的STOP2研究中呼吸道病毒感染的患病率及临床影响
Ann Am Thorac Soc. 2024 Apr;21(4):595-603. doi: 10.1513/AnnalsATS.202306-576OC.
7
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one allele: 144-week interim results from a 192-week open-label extension study.在至少携带一个 F508del 等位基因的囊性纤维化患者中，elexacaftor/tezacaftor/ivacaftor 的长期安全性和疗效：一项为期 192 周的开放标签扩展研究的 144 周中期结果。
Eur Respir J. 2023 Dec 7;62(6). doi: 10.1183/13993003.02029-2022. Print 2023 Dec.
8
Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations.囊性纤维化肝胆道疾病筛查、评估和管理的共识建议。
Hepatology. 2024 May 1;79(5):1220-1238. doi: 10.1097/HEP.0000000000000646. Epub 2023 Oct 26.
9
Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.依伐卡托/泰他卡托/埃他卡托治疗与抑郁相关事件。
Am J Respir Crit Care Med. 2024 Feb 1;209(3):299-306. doi: 10.1164/rccm.202308-1525OC.
10
Incidence of fibrosing colonopathy with pancreatic enzyme replacement therapy in patients with cystic fibrosis.囊性纤维化患者使用胰腺酶替代治疗后的纤维化结肠病的发生率。
J Cyst Fibros. 2023 Nov;22(6):1017-1023. doi: 10.1016/j.jcf.2023.08.013. Epub 2023 Oct 23.
Zotero 插件